Insights on Pharmaceuticals & Medical Products


Digital therapeutics: Preparing for takeoff

– Understanding the obstacles to the adoption of digital therapeutics is key to understanding how they might be overcome.

Special Collections

Biopharma Frontiers:
What the future holds for the industry

Industry leaders and key stakeholders offer perspectives to inspire discussion and constructive debate.

The pharma launchpad

Ideas for pharma and biotech looking to invest for launch success.

Want to learn more about how we help clients in Pharmaceuticals & Medical Products?

More insights


The digital imperative for pharma companies in Japan

– Five facts showing that companies should invest in digital customer engagement in Japan.

The changing face of medical-device design

– Design can help craft a standout patient experience. Here, three leaders discuss how the discipline is improving medical products... and driving innovation.

Exploring the potential of digital therapeutics

– Three European digital-health CEOs share their perspective on digital therapeutics.

Digital in R&D: The $100 billion opportunity

– Digital promises to transform R&D productivity over the next decade. What will it take to realize this potential?

The medtech opportunity for Japanese companies

– A large-scale commitment to growth in healthcare technologies could be a key contributor to the Japanese economy.

How medical-device CEOs can navigate digital disruption in healthcare

– Medical-device companies will need to reinvent themselves to stay competitive. Now’s the time to craft a strategy and scale... a transformation.

Innovating at the speed of the 21st century in pharmaceuticals

– The CEO of Eli Lilly offers perspectives on accelerating change in the industry.

Elevating the impact of medical affairs in Japan

– Recent research sheds light on the value of the medical channel and what it takes to have a high-performing medical-affairs organization.

Biopharma valuations—onward and upward?

– Companies focused on biopharma have done well in capital markets. A closer look at performance helps explain why.

What’s next for pharma innovation in China

– Three prominent Chinese executives discuss the progress of local companies in drug innovation and the evolving regulatory environment.

The growth imperative for medical-device companies

– Recent valuations have been driven by high expectations of growth. Can your company deliver?

Connect with our Pharmaceuticals & Medical Products Practice